Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTK inhibitors for vitreoretinal lymphoma (phase II, single-arm)
ChiCTR2000037921Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Aug 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and zanubrutinib in vitreoretinal lymphoma (PVRL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Tongren Hospital. Primary endpoint: Disease Control Rate. Started Aug 2020; status: recruiting.
02
Drugs
ibrutinibzanubrutinib
03
Conditions
vitreoretinal lymphoma (PVRL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2000037921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037921.